MARIETTA, Ga., Nov. 10, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences:
Craig-Hallum 16th Annual Alpha Select Conference | New York, NY
Tuesday, November 18, 2025
1:1 sessions
Canaccord MedTech, Diagnostics and Digital Health & Services Forum | New York, NY
Thursday, November 20, 2025
1:1 sessions
Investors interested in meeting with senior management at these events may contact their respective Craig-Hallum or Canaccord representative.
About MIMEDX
MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com.
Contact:
Matt Notarianni
Investor Relations
470-304-7291
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$7.47 |
| Daily Change: | -0.01 -0.13 |
| Daily Volume: | 902,147 |
| Market Cap: | US$1.110B |
November 13, 2025 October 29, 2025 October 06, 2025 July 30, 2025 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
